Evidence map›Paper›PMID 29535805›Full record

ArticleOncotarget2018

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.

Christine Koch, Anna M Schwing, Eva Herrmann, Markus Borner, Eduardo Diaz-Rubio, Efrat Dotan, Jaime Feliu, Natsuko Okita, John Souglakos, Hendrik T Arkenau and 7 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 8 countries.

Christine KochDepartment of Gastroenterology, University Liver and Cancer Centre, Frankfurt, Germany.
Anna M SchwingDepartment of Gastroenterology, University Liver and Cancer Centre, Frankfurt, Germany.
Eva HerrmannInstitute of Biostatistics and Mathematical Modelling, Johann Wolfgang Goethe-University, Frankfurt, Germany.
Markus BornerMedical Oncology Institute, Inselspital, Bern, Switzerland.
Eduardo Diaz-RubioDepartment of Oncology, Hospital Clínico San Carlos, Madrid, Spain.
Efrat DotanFox Chase Cancer Center, Philadelphia, PA, USA.
Jaime FeliuDepartment of Medical Oncology, La Paz University Hospital, CIBERONC, Madrid, Spain.
Natsuko OkitaNational Cancer Center, Tokyo, Japan.
John SouglakosDepartment of Medical Oncology, University Hospital of Heraklion, University of Crete, Crete, Greece.
Hendrik T ArkenauSarah Cannon Research Institute, London, UK.
Rainer PorschenKlinikum Bremen Ost, Bremen, Germany.
Miriam KoopmanDepartment of Medical Oncology, University Medical Centre, Utrecht, The Netherlands.
Cornelis J A PuntDepartment of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Aimery de GramontL'Institut Hospitalier Franco-Britannique, Paris, France.
Christophe TournigandUniversity of Paris Est Creteil, Henri-Mondor Hospital, Créteil, France.
Stefan ZeuzemDepartment of Gastroenterology, University Liver and Cancer Centre, Frankfurt, Germany.
Joerg TrojanDepartment of Gastroenterology, University Liver and Cancer Centre, Frankfurt, Germany.
Centro de Investigación Biomédica en Red de Cáncer · ESFox Chase Cancer Center · USGoethe University Frankfurt · DEHospital Clínico San Carlos · ESInstitut Hospitalier Franco Britannique · FRKlinikum Bremen-Mitte · DESarah Cannon Research Institute · GBUniversité Paris-Est Créteil · FRUniversity Hospital of Bern · CHUniversity Medical Center Utrecht · NLUniversity of Amsterdam · NLUniversity of Crete · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this meta-analysis was to evaluate efficacy and safety of first-line chemotherapy with or without a monoclonal antibody in elderly patients (≥ 70 years) with metastatic colorectal cancer (mCRC), since they are frequently underrepresented in clinical trials.

resultsIndividual data from 10 studies were included. From a total of 3271 patients, 604 patients (18%) were ≥ 70 years (median 73 years, range 70-88). Of these, 335 patients were treated with a bevacizumab-based first-line regimen and 265 were treated with chemotherapy only. The median PFS was 8.2 vs. 6.5 months and the median OS was 16.7 vs. 13.0 months in patients treated with and without bevacizumab, respectively. The safety profile of bevacizumab in combination with first-line chemotherapy did not differ from published clinical trials. MATERIALS AND

methodsPubMed and Cochrane Library searches were performed on 29 April 2013 and studies published to this date were included. Authors were contacted to request progression-free survival (PFS), overall survival (OS) data, patient data on treatment regimens, age, sex and potential signs of toxicity in patients ≥ 70 years of age.

conclusionsThis meta-analysis suggests that the addition of bevacizumab to standard first-line chemotherapy improves clinical outcome in elderly patients with mCRC and is well tolerated.

Indexed as

bevacizumabelderlyfirst-line chemotherapymetastatic colorectal cancer

Identifiers

PMID29535805
PMCPMC5828201
OpenAlexW2777292243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.